Chronic myeloid leukemia

Hagop Kantarjian, Jorge Cortes, Elias Jabbour, Susan O’Brien

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter summarizes the knowledge regarding the molecular biology of chronic myeloid leukemia (CML) and the treatment modalities, including novel breakpoint cluster region-v-abl Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL1) tyrosine kinase inhibitors (TKIs). The discovery that BCR-ABL1 plays a pivotal role in the pathogenesis of CML set the stage for the development of therapeutic strategies aimed at inhibiting this kinase and its downstream signals. In CML-blastic phase the use of TKI in combination with chemotherapy is superior to single-agent TKI or chemotherapy alone, even after failure of TKI or chemotherapy. The transition from CML-chronic phase to CML-accelerated phase is subclinical and laboratory monitoring is necessary to detect disease progression. The different CML phases predict for very different survival probabilities. However, the prognosis is variable among patients in the same phase of the disease. Several patient and disease characteristics have been found to be prognostically useful and have been used to generate prognostic models.

Original languageEnglish (US)
Title of host publicationMolecular Hematology
Publisherwiley
Pages71-86
Number of pages16
ISBN (Electronic)9781119252863
ISBN (Print)9781119252870
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Keywords

  • Chemotherapy
  • Chronic myeloid leukemia
  • Molecular biology
  • Prognostic models
  • Therapeutic strategies
  • Treatment modalities
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Chronic myeloid leukemia'. Together they form a unique fingerprint.

Cite this